ALS Thumbnail

JMCP Outsert - ALS

Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. The etiology of ALS is unknown, however it is thought to be due to a combination of genetic predisposition, environmental exposures, and agingrelated dysfunction. The clinical presentation of ALS varies depending on which motor neurons are affected. ALS commonly presents with localized weakness that progresses to muscle paralysis, respiratory failure, and death.
Market Insights, Amyotrophic Lateral Sclerosis
AMCP Regulatory NewsBreaks

June 30, 2023: CMS Issues Revised IRA Negotiation Guidance

On June 30, 2023, the Centers for Medicare and Medicaid Services (CMS) issued final guidance on the Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program for the initial price applicability year 2026 (Revised Guidance).
AMCP Podcast Series Featured Episode

Fundamentals of Managed Care Pharmacy Training Program

Host Fred Goldstein invites Ruby Singh, Senior Vice President of Education and Instruction and Brittany Henry, Director of Education Programs, with AMCP, to discuss the brand-new 3rd edition of the AMCP Fundamentals of Managed Care Pharmacy Training Program scheduled for release July 2023.
Non Small Cell Lung Cancer Thumbnail

Best Practice Handout – Health Plan Best Practice – Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Market Insights, Cancer – Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer Thumbnail

JMCP Outsert - Precision Oncology in NSCLC (Biomarker)

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Precision Medicine